Challener, Cynthia
October 2007
ICIS Chemical Business;10/1/2007, Vol. 272 Issue 12, p22
Trade Publication
The article contemplates on the Good Manufacturing Practice regulations to be followed by pharma manufacturers outside the Europe to meet the set quality standards. The lack of inspections to determine compliance with GMP and absence of sanctions for non compliance members has made possible the export of lower-quality pharmaceutical products to European Union nations. Information on various measures taken by European Fine Chemicals Group to maintain quality standards is also presented.


Related Articles

  • EU Raises API Standards: A Curse in Disguise? Milmo, Sean // Pharmaceutical Technology Europe;Sep2013, Vol. 25 Issue 9, p16 

    The article offers information on the implementation of the European Union Falsified Medicines Directive (FMD) standards for good manufacturing practices (GMP) for improving the quality of the imported active pharmaceutical ingredients (API). It informs that according to the new standards, API...

  • EU requires guarantee that imported substances meet GMP.  // Reactions Weekly;7/6/2013, Issue 1460, p3 

    The article reports that under the Falsified Medicines Directive active substances and medicines imported into the European Union (EU) will require to be accompanied by written confirmation about manufacturing plant meeting standards of good manufacturing practice (GMP) from July 2, 2013.

  • India arrives as pharma giant.  // InTech;Apr2007, Vol. 54 Issue 4, p11 

    The article reports that the pharmaceutical industry in India would be close to $10 billion by 2010, according to the ARC Advisory Group. It reveals that the industry is around $8 billion with export revenues accounting for 35% to 40%. Domestic pharmaceutical companies produce drugs belonging to...

  • GMP Conformity: A Ukrainian Perspective. Sinichkina, Lana; Cherniavskyi, Leonid // Pharmaceutical Technology Europe;Nov2014, Vol. 26 Issue 11, p8 

    The article focuses on the implementation of Good Manufacturing Practice Standards (UA-GMP) by the Ministry of Healthcare of Ukraine. Topics discussed include adoption of GMP to ensure the quality of medicinal products, State Administration of Ukraine of Medicinal Products controlling...

  • Annex 16 for the 21st century. Hall, Alex // GMP Review;Oct2013, Vol. 12 Issue 3, p4 

    The article offers information on changes to the European Union's (EU) Good Manufacturing Practice (GMP) Annex 16 for the pharmaceutical industry. Topics discussed include selecting samples instead of identifying all supply chains, sharing of responsibilities by a qualified person (QP) with...

  • Is GMP Annex 11 Europe's Answer to 21 CFR 11? McDowall, Robert D. // LC-GC Europe;Apr2011, Vol. 24 Issue 4, p208 

    The author discusses the impact of the Good Manufacturing Practice (GMP) Annex 11 ruling of the European Union (EU) on chromatography data systems (CDSs) in Europe. He states that the 21 Code of Federal Regulations (CFR) 11 legislation requires a CDS to have documentation which is either...

  • Sterile production according to the new EU GMP Annex 1: a locus on capping. Mangel, Andreas // Pharmaceutical Technology Europe;Aug2010, Vol. 22 Issue 8, p26 

    The article focuses on regulations governing sterile manufacture of pharmaceuticals in Europe. The revised version of the European Union (EU) Good Manufacturing Practice (GMP) Guide Annex 1 "Manufacture of Sterile Medicinal Products" with emphasis on capping of vials is tackled. Case studies to...

  • Certificates of Test -- What are the European GMP Requirements? McCrarght, Ashley; Randall, Norman // Pharmaceutical Technology Europe;Mar2004, Vol. 16 Issue 3, p22 

    This article examines European differences in GMP requirements for the acceptance of Certificates of Tests. Within the premises of European Union (EU) pharmaceutical manufacturers, there is typically up to 3 weeks' worth of supplied materials inventory waiting to be tested. Quality control (QC)...

  • APIs: Why EU authority oversight is vital. Oldenhof, Chris // Pharmaceutical Technology Europe;Mar2006, Vol. 18 Issue 3, p32 

    The article explains the importance of the European Union's (EU) introduction of regulations to ensure that all active pharmaceutical ingredients (API) destined for member states are compliant with the same good manufacturing practice guidelines irrespective of their country of manufacture. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics